Solid biosciences receives rare pediatric disease designation from the fda for duchenne muscular dystrophy gene therapy candidate sgt-003

– sgt-003 granted rare pediatric disease, orphan drug and fast track designations in u.s. – – site initiations scheduled for april; patient dosing expected to begin in q2 2024 – charlestown, mass., april 01, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the u.s. food and drug administration (fda) has granted rare pediatric disease designation for sgt-003, the company's next-generation duchenne muscular dystrophy (duchenne) gene therapy candidate.
SLDB Ratings Summary
SLDB Quant Ranking